Hospira's Heparin Sodium ANDA090571 Receives AP Status from FDA
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Heparin Sodium submitted by Hospira Inc.
Asset
Hospira
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of Hospira's Heparin Sodium under ANDA090571 is significant as it positions the company competitively within the anticoagulant market. This approval could lead to increased market share for Hospira, necessitating close attention to launch strategies and competitor responses.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for market launch and any potential competitive responses from other manufacturers.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.